Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMX0EZJ)

• Drug Name: Prothionamide Drug Info
• Synonyms: Ektebin; Peteha; Prothionamidum; Protionamid; Protionamida; Protionamide; Protionamidum; Protionizina; Tebeform; Trevintix; Tuberex; RP 9778; TH 1321; Prothionamide (JP15); Protionamida [INN-Spanish]; Protionamide (INN); Protionamide [INN:DCF]; Protionamidum [INN-Latin]; TH-1321; Trevintix (TN); 2-Propyl-4-pyridinecarbothioamide; 2-Propyl-4-thiocarbamoylpyridine; 2-Propyl-thioisonicotinamide; 2-Propylisonicotinylthioamide; 2-Propylthioisonicotinamide; 2-propylpyridine-4-carbothioamide; 4-Pyridinecarbothioamide, 2-propyl-(9CI); 9778 R.P; 9778 R.P.
• Therapeutic Class: Antituberculosis Agents
• Cross-matching ID:
  PubChem CID: 666418
  ChEBI ID: CHEMBL32066
  CAS Number: CAS 14222-60-7
  TTD Drug ID: D0L7UQ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Glutamatergic synapse	1.99	0.00e+0	97/114 (85.09%)	GNG11;PPP3CA;GNAS;...
Retrograde endocannabinoid signaling	1.91	2.32e-2	118/148 (79.73%)	GNG11;PRKCA;PRKCB;...
Mucin type O-glycan biosynthesis	1.88	1.55e-2	20/36 (55.56%)	GALNT3;GALNT7;B4GALT5;...
Renin secretion	1.87	1.45e-2	61/69 (88.41%)	PPP3CA;GNAS;CALML5;...
Pyrimidine metabolism	1.87	1.16e-2	40/56 (71.43%)	NT5E;TYMS;DPYD;...
Melanogenesis	1.86	9.66e-3	74/101 (73.27%)	GNAS;KRAS;PRKCA;...
Various types of N-glycan biosynthesis	1.85	8.28e-3	26/39 (66.67%)	HEXB;MGAT2;RPN2;...
Parkinson disease	1.83	1.59e-2	176/249 (70.68%)	GNAS;COX7B;ATP5PD;...
Circadian entrainment	1.81	1.93e-2	85/97 (87.63%)	GNG11;GNAS;PRKCA;...
Dopaminergic synapse	1.81	1.74e-2	115/132 (87.12%)	GNG11;PPP3CA;GNAS;...
Endocrine and other factor-regulated calcium reabsorpti...	1.80	1.69e-2	49/53 (92.45%)	GNAS;PRKCA;PRKCB;...
Salivary secretion	1.78	1.93e-2	76/93 (81.72%)	LYZ;GNAS;PRKCA;...
Morphine addiction	1.75	2.23e-2	80/91 (87.91%)	GNG11;GNAS;PRKCA;...
Long-term potentiation	1.73	2.57e-2	61/67 (91.04%)	PPP3CA;KRAS;PRKCA;...
N-Glycan biosynthesis	1.72	2.47e-2	38/50 (76%)	DPM1;MGAT2;RPN2;...
Other types of O-glycan biosynthesis	1.72	2.39e-2	29/47 (61.7%)	GALNT3;GALNT7;C1GALT1C1;...
Graft-versus-host disease	1.71	2.39e-2	32/42 (76.19%)	HLA-DMB;KLRD1;HLA-A;...
Natural killer cell mediated cytotoxicity	1.71	2.32e-2	99/131 (75.57%)	PPP3CA;KLRK1;KRAS;...
Cholinergic synapse	1.71	2.20e-2	99/113 (87.61%)	GNG11;KRAS;PRKCA;...
African trypanosomiasis	1.69	2.43e-2	32/37 (86.49%)	PRKCA;PRKCB;PLCB1;...
Long-term depression	1.69	2.32e-2	55/60 (91.67%)	GNAS;KRAS;PRKCA;...
Allograft rejection	1.68	2.32e-2	32/38 (84.21%)	HLA-DMB;HLA-A;GZMB;...
Antigen processing and presentation	1.67	2.42e-2	60/78 (76.92%)	HSPA8;HLA-DMB;KLRD1;...
Oxytocin signaling pathway	1.67	2.37e-2	128/154 (83.12%)	PPP3CA;GNAS;KRAS;...
Type I diabetes mellitus	1.66	2.46e-2	38/43 (88.37%)	PTPRN2;HLA-DMB;HLA-A;...
Thermogenesis	1.65	2.59e-2	173/232 (74.57%)	GNAS;KRAS;COX7B;...
Ribosome	1.65	2.53e-2	113/158 (71.52%)	RPS27L;MRPS2;RPL26L1;...
Proteasome	1.64	2.52e-2	44/46 (95.65%)	PSMB10;PSMA2;PSMA7;...
Amphetamine addiction	1.64	2.44e-2	57/69 (82.61%)	PPP3CA;GNAS;PRKCA;...
Prion disease	1.64	2.36e-2	209/273 (76.56%)	HSPA8;PPP3CA;COX7B;...
Glutathione metabolism	-1.71	4.59e-2	43/57 (75.44%)	GSTP1;RRM1;IDH2;...
Collecting duct acid secretion	-1.72	4.65e-2	22/27 (81.48%)	ATP6V1A;ATP6V0A1;ATP6V1E1;...
Pentose phosphate pathway	-1.75	3.89e-2	25/30 (83.33%)	PFKL;RBKS;GPI;...
Epithelial cell signaling in Helicobacter pylori infect...	-1.76	4.65e-2	62/70 (88.57%)	CSK;ATP6V1A;ATP6V0A1;...
Fructose and mannose metabolism	-1.85	1.69e-2	30/33 (90.91%)	HKDC1;PFKFB2;HK1;...
Rheumatoid arthritis	-1.87	1.27e-2	78/93 (83.87%)	IL18;ICAM1;ATP6V1A;...
Steroid biosynthesis	-2.19	0.00e+0	19/20 (95%)	EBP;SC5D;HSD17B7;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast

Breast adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
MCF7	CVCL_0031	Homo sapiens	10uM	6H, 24H	Hide ▲

Colon

Colorectal adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HT-29	CVCL_0320	Homo sapiens	10uM	6H	Hide ▲

Hematopoietic system

Normal

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
ASC	CVCL_U602	Homo sapiens	10uM	24H	Show ▼

Kidney

Normal (Immortalized)

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HA1E	CVCL_0284	Homo sapiens	10uM	6H, 24H	Show ▼

Liver

Hepatoblastoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
Hep G2	CVCL_0027	Homo sapiens	10uM	6H	Show ▼

Hepatocellular carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HuH-7	CVCL_0336	Homo sapiens	20uM	72H	Show ▼

Lung

Lung adenocarcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A549	CVCL_0023	Homo sapiens	10uM	6H, 24H	Show ▼

Non-small cell lung carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
HCC515	CVCL_5134	Homo sapiens	10uM	6H, 24H	Show ▼

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	10uM	6H, 24H	Show ▼
VCaP	CVCL_2235	Homo sapiens	10uM	6H, 24H	Show ▼

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	10uM	6H	Show ▼